Recipient beta-blocker of prevention weaning piggy diarrhea and piggy oedematous disease, preparing and application

Abstract

The invention relates to a receptor antagonist for preventing diarrhea occurring on the weaned piglets and edema disease occurring on the piglets, a preparation method and an application. The receptor antagonist of the invention is an assemblage series of recombinant strains of probiotics, and is a MisL-Beta recombinant vector which expresses FedF formed by F18 or Fed adhering to prime subunit gene, and FaeG formed by K88 or F4 or Fae adhering to the prime subunit gene, based on the recombinant strain EP2 of the probiotics of escherichia coli with pig origin advantage and strain LP2 of probiotics of lactobacillus with pig origin advantage. The surface of the cell is good to express antigen technology, so after the piglets orally administrate the cell, the cell can colonize, sedentarily live and proliferate in the intestine. Furthermore, the cell on the surface of the epithelium of the intestine functionally shows secretory expression of highly conservative and cofunctional adhesins FedF and FaeG, that is, the receptor binding domain of F18 and K88 adhesins, which is preferentially bound with the surface of the epithelium of the intestine of the piglets, and thus the diarrhea occurring on the weaned piglets and the edema disease occurring on the piglets are controlled. The invention overcomes the defects that the present antibiotics are almost ineffective in the clinical treatment as most of piglets suffering from the edema disease die though treated by the present antibiotics, and the present antibiotics causes multiple drug resistance.

Description

technical field [0001] The invention relates to a biological agent-receptor blocker, in particular to a receptor blocker for preventing weaned piglet diarrhea and piglet edema disease, preparation and application. Background technique [0002] Before the present invention, there is not any commercialized vaccine for the prevention of weaning piglet diarrhea and piglet edema disease in the whole world, but only when weaning piglet diarrhea and piglet edema disease cases occur clinically, all passive clinical treatment of antibiotics is used. To a certain extent, the diarrhea rate of newborn piglets and weaned piglets has been reduced, but the clinical antibiotic treatment for piglet edema disease cases is basically ineffective. A variety of drug-resistant enterotoxigenic Escherichia coli (ETEC) F18 and K88 strains are continuously produced and spread at the animal level, and cause antibiotic inefficiency and accumulation in animals, and also cause disturbance of normal flora ...

AI Technical Summary

Problems solved by technology

[0002] Before the present invention, there is not any commercialized vaccine for the prevention of weaning piglet diarrhea and piglet edema disease in the whole world, but only when weaning piglet diarrhea and piglet edema disease cases occur clinically, antibiotics are all passively used for clinical treatment. To a certain extent, the diarrhea rate of newborn piglets and weaned piglets has been reduced, but the clinical antibiotic treatment for piglet edema disease cases is basically ineffective. A variety of drug-resistant enterotoxigenic Escherichia coli (ETEC) F18 and K88 strains are continuously produced and spread at the animal body level, and cause antibiotic inefficiency and accumulation in animals, and also cause disturbance of normal flora in the gastrointestinal tract of animals , indigestion, cause gastrointestinal tract and body resistance to decline, prone to secondary or concurrent multiple diseases

Images